Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma

Paolo Strati(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Anne Rain Brown, Bryan Do, Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Michael R. Green(Harvard University), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Grace Watson, Catherine M. Claussen, Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Sandra B. Horowitz, Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center)
Blood Advances
July 9, 2020
10.1182/bloodadvances.2020002328
Cited by 195

Related Papers

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
|Blood|2010|1.3k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574